Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.

Francesca Maria Tumminello, Gaetano Leto, Giuseppe Badalamenti, Fabio Fulfaro, Lorena Incorvaia, Giuseppe Badalamenti, Calogero D'Amico, Francesca M. Tumminello, Fabio Fulfaro, Gaetano Leto

Risultato della ricerca: Article

28 Citazioni (Scopus)


The clinical significance of serum interleukin-6 (IL-6) and its correlation with cystatin C (Cyst C), an endogenous inhibitor of cysteine proteinase cathepsin K, was investigated by immunoassays in patients with bone metastasis from breast cancer (BCa) or prostate cancer (PCa). Additional studies were also performed in these patients to assess the effects of zoledronic acid (ZA) administration on the circulating levels of these molecules. Mean IL-6 and Cyst C serum concentrations were signifi- cantly increased in BCa patients and in patients with primary osteoporosis (PU) compared to healthy subjects (HS). However, Cyst C, but not IL-6, resulted significantly more elevated in BCa patients than in PU patients. Fur- thermore, in BCa patients no correlation was highlighted between IL-6 and Cyst C or between these molecules and some clinicobiological parameters of malignant progres- sion. Mean IL-6 levels were also higher in PCa patients and in patients with benign prostatic hyperplasia (BPH) than in HS while Cyst C resulted significantly higher in PCa but not in BPH patients as compared to HS. In PCa patients, a positive correlation was highlighted between IL-6 and number of bone metastases or serum prostate-specific antigen but not with the Gleason score. Conversely, Cyst C levels did not correlate with any of the parameters consid- ered above or with IL-6. Receiver operating characteristic (RUC) curve analysis showed a poor diagnostic accuracy of IL-6 and Cyst C to detect BCa patients with skeletal metastases while, in PCa patients, only IL-6 showed a fair diagnostic performance in this respect. Finally, the admin- istration of ZA to patients with bone metastases induced a statistically significant increase of serum IL-6 and Cyst C only PCa patients with bone metastasis. These data indicate that IL-6 and Cyst C may be regarded as novel targets for cancer treatment and as markers of increased osteoblastic activity associated to bisphosphonate treatments in PCa patients with bone metastases.
Lingua originaleEnglish
pagine (da-a)10-15
Numero di pagine6
Stato di pubblicazionePublished - 2009

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.'. Insieme formano una fingerprint unica.

Cita questo